Thyroid Disorders in the Context of the COVID-19 Pandemic
-
By
-
Majd Irsheid
-
Nitzan Burrack
-
Merav Fraenkel
-
Eli Hershkovitz
-
Uri Yoel
-
April 22, 2026
Clinical Scorecard: Thyroid Disorders in the Context of the COVID-19 Pandemic
At a Glance
| Category | Detail |
|---|
| Condition | Thyroid Disorders (Hashimoto’s Thyroiditis, Graves’ Disease, Subacute Thyroiditis) |
| Key Mechanisms | Autoimmune responses triggered by COVID-19 infection. |
| Target Population | Adults (≥16 years) in Clalit Health Services, Israel. |
| Care Setting | Population-based healthcare study. |
Key Highlights
- 30% increase in Hashimoto’s Thyroiditis incidence during the pandemic.
- Non-significant upward trend in Graves’ Disease incidence.
- 54% reduction in Subacute Thyroiditis incidence during the pandemic.
- Significant female predominance (77%) across thyroid disorders.
- Study utilized interrupted time series analysis for incidence comparison.
Guideline-Based Recommendations
Diagnosis
- Utilize ICD-9 codes, laboratory results, and medication dispensing data for identifying new cases.
Management
- Monitor thyroid function tests in patients with COVID-19 for potential thyroid dysfunction.
Monitoring & Follow-up
- Regular follow-up for patients with autoimmune thyroid disorders post-COVID-19.
Risks
- Increased risk of autoimmune thyroid disease following COVID-19 infection.
Patient & Prescribing Data
Adults aged ≥16 years in the Clalit Health Services.
Consider potential thyroid dysfunction in COVID-19 survivors.
Clinical Best Practices
- Conduct population-level studies to understand the impact of COVID-19 on thyroid health.
- Validate diagnostic codes with laboratory and imaging criteria to avoid misclassification.
Related Resources & Content
